peptide-solutions
TIRZEPATIDE
Dual GLP-1/GIP receptor agonist for metabolic research
Research Compound
Manufactured under strict quality control protocols with full analytical testing. Certificate of Analysis (COA) available upon request.
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment. Research explores its exceptional efficacy in weight reduction and metabolic improvement.
Compound Specifications
Scientific Documentation
Research Reference
Detailed research information, pharmacological profile, and handling specifications
Mechanism of Action
A single molecule activating both GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). The dual mechanism produces greater insulin secretion, appetite suppression, and fat cell remodeling than GLP-1 agonism alone.
Research Use Only Disclaimer
This product is intended strictly for laboratory and research purposes only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm that you are an authorized researcher or institution and that this product will be used solely for legitimate research purposes in compliance with all applicable laws and regulations.
Related Compounds
Other research peptides you may be interested in
SEMAGLUTIDE
GLP-1 receptor agonist for metabolic research
from $78
RETATRUTIDE
Triple-action GLP-1/GIP/Glucagon receptor agonist
from $125
TESAMORELIN 10MG
GHRH analog for metabolic and body composition research
$65